Tvardi Therapeutics, Inc. (TVRD)
3.84
-0.11
(-2.78%)
USD |
NASDAQ |
Feb 04, 16:00
3.84
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 36.02M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -72.45% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 4.981 |
| Price to Book Value | 1.293 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0082 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.64% |
Profile
| Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX. |
| URL | http://tvarditherapeutics.com |
| Investor Relations URL | https://ir.tvarditherapeutics.com/investor-relations |
| HQ State/Province | Texas |
| Sector | |
| Industry | |
| Next Earnings Release | Mar. 11, 2026 (est.) |
| Last Earnings Release | Nov. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX. |
| URL | http://tvarditherapeutics.com |
| Investor Relations URL | https://ir.tvarditherapeutics.com/investor-relations |
| HQ State/Province | Texas |
| Sector | |
| Industry | |
| Next Earnings Release | Mar. 11, 2026 (est.) |
| Last Earnings Release | Nov. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |